Phase III Results: Tiotropium a Respimat® Significantly Reduces Exacerbations in Asthma Patients Still Symptomatic Despite ICS/laba Treatment (Part 2 of 2)

Uploaded by Addiction Videos on October 5, 2013 at 9:28 pm

Data from the PrimoTinA-asthmaTM Phase III studies presented for the first time today at the 2012 European Respiratory Society (ERS) congress show that tiotropium significantly reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICSB/LABAC.1 Tiotropium also significantly improved lung function in symptomatic asthma patients on ICS/LABA.2
Powered by NewsLook.com
Producer : Business Wire

Google+
  • Rating:
  • Views:109 views

Related Videos:

No Related Videos

Comments

Write a comment